These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 18940388

  • 1. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
    Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, Yang M, Cryan E, Rybczynski P, Demarest K.
    Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
    [Abstract] [Full Text] [Related]

  • 2. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
    Tsunoda M, Kobayashi N, Ide T, Utsumi M, Nagasawa M, Murakami K.
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E833-40. PubMed ID: 18212024
    [Abstract] [Full Text] [Related]

  • 3. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
    Jeong HW, Lee JW, Kim WS, Choe SS, Shin HJ, Lee GY, Shin D, Lee JH, Choi EB, Lee HK, Yon GH, Cho B, Kim HR, Choi SH, Chung YS, Park SB, Chung H, Ro S, Kim JB.
    Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
    [Abstract] [Full Text] [Related]

  • 4. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY.
    Eur J Pharmacol; 2008 Oct 24; 595(1-3):119-25. PubMed ID: 18727927
    [Abstract] [Full Text] [Related]

  • 5. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC.
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar 24; 296(3):G543-52. PubMed ID: 19136377
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
    Ide T, Tsunoda M, Mochizuki T, Murakami K.
    Med Sci Monit; 2004 Oct 24; 10(10):BR388-95. PubMed ID: 15448592
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH, Hwang JK.
    Diabetes; 2008 Mar 24; 57(3):737-45. PubMed ID: 18065517
    [Abstract] [Full Text] [Related]

  • 8. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF.
    Circulation; 2007 Sep 18; 116(12):1404-12. PubMed ID: 17724261
    [Abstract] [Full Text] [Related]

  • 9. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN, Tao RY, Tian JY, Liu GT, Ye F.
    Life Sci; 2008 May 07; 82(19-20):983-90. PubMed ID: 18417155
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor alpha is involved in the regulation of lipid metabolism by ginseng.
    Yoon M, Lee H, Jeong S, Kim JJ, Nicol CJ, Nam KW, Kim M, Cho BG, Oh GT.
    Br J Pharmacol; 2003 Apr 07; 138(7):1295-302. PubMed ID: 12711630
    [Abstract] [Full Text] [Related]

  • 11. Activation of peroxisome proliferator-activated receptor-α enhances fatty acid oxidation in human adipocytes.
    Lee JY, Hashizaki H, Goto T, Sakamoto T, Takahashi N, Kawada T.
    Biochem Biophys Res Commun; 2011 Apr 22; 407(4):818-22. PubMed ID: 21443859
    [Abstract] [Full Text] [Related]

  • 12. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells.
    Nagasawa M, Akasaka Y, Ide T, Hara T, Kobayashi N, Utsumi M, Murakami K.
    Biochem Pharmacol; 2007 Dec 15; 74(12):1738-46. PubMed ID: 17904533
    [Abstract] [Full Text] [Related]

  • 13. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C, Wang LL, Liu HY, Zhou XB, Cao YL, Li S.
    Acta Pharmacol Sin; 2006 Feb 15; 27(2):223-8. PubMed ID: 16412273
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y.
    Diabetes; 2007 Aug 15; 56(8):2036-45. PubMed ID: 17536062
    [Abstract] [Full Text] [Related]

  • 15. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
    Chakrabarti R, Misra P, Vikramadithyan RK, Premkumar M, Hiriyan J, Datla SR, Damarla RK, Suresh J, Rajagopalan R.
    Eur J Pharmacol; 2004 May 03; 491(2-3):195-206. PubMed ID: 15140637
    [Abstract] [Full Text] [Related]

  • 16. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.
    Mol Endocrinol; 2005 Jun 03; 19(6):1593-605. PubMed ID: 15831517
    [Abstract] [Full Text] [Related]

  • 17. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
    Wang ZJ, Liu Q, Li PP, Zou CH, Shen ZF.
    Eur J Pharmacol; 2008 Feb 02; 580(1-2):277-83. PubMed ID: 18048028
    [Abstract] [Full Text] [Related]

  • 18. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
    Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ.
    Acta Pharmacol Sin; 2005 May 02; 26(5):575-80. PubMed ID: 15842776
    [Abstract] [Full Text] [Related]

  • 19. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
    Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK, Larsen TS.
    J Mol Cell Cardiol; 2008 Jan 02; 44(1):201-9. PubMed ID: 17931655
    [Abstract] [Full Text] [Related]

  • 20. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.